Assessment of Orthographic Similarity of Drugs Names between Iran and Overseas Using the Solar Model

  • Nazanin ABOLHASSANI Dept. of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  • Ali AKBARI SARI Dept. of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  • Arash RASHIDIAN Dept. of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  • Mansoor RASTEGARPANAH Dept. of Clinical Pharmacy, College of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Keywords: Patient safety, Drug proprietary names, Orthographic similarity, General office of trademarks registry, Solar model, Iran

Abstract

Background: The recognition of patient safety is now occupying a prominent place on the health policy agenda since medical errors can result in adverse events. The existence of confusing drug names is one of the most common causes of medication errors. In Iran, the General Office of Trademarks Registry (GOTR), for four years (2010-2014) was responsible for approving drug proprietary names. This study aimed to investigate the performance of the GOTR in terms of drug names orthographic similarity using the SOLAR model.Methods: First, 100 names were randomly selected from the GOTR’s database. Then, each name was searched through pharmaceutical websites including Martindale (the Complete Drug Reference published by Pharmaceutical Press), Drugs.com and Medicines Complete. Pair of drugs whose names look orthographically similar with different indications were identified. Then, the SOLAR model was utilized to determine orthographic similarity between all pair of drug names.Results: The mean of match values of these 100 pairs of drug was 77% indicating the high risk of similarity. The match value for most of the reviewed pairs (92%) was high (≥66%). This value was medium (≥ 33% and <66%) just for 8% of the pairs of drug. These results indicate high risk of confusion due to similarity of drug names.Conclusion: The stewardship of the GOTR in patient safety considerations is fundamentally problematic. Thus, as a best practice, we recommend that proprietary names of drugs be evaluated by an entity within the health system. While an entity within the health system should address patient safety considerations, the GOTR is responsible for intellectual property rights.  

References

Mello MM, Kelly CN, Brennan TA (2005). Fostering rational regulation of patient safety. J Health Polit Policy Law, 30(3):375-426.

Litman L. Mapping Medication Errors and Information Management Solutions. [Master thesis]. Centre for Health Infor-matics City University, London, UK; 2007.

Lambert BL, Chang K-Y, Gupta P (2003). Effects of frequency and similarity neigh-borhoods on pharmacists’ visual percep-tion of drug names. Soc Sci Med, 57(10):1939-55.

World Health Organization (2007). WHO Collaborating Centre on Patient Safety Solutions. Control of Concentrated Elec-trolyte Solutions Patient Safety Solutions http://www.who.int/patientsafety/solutions/patientsafety/PS-Solution5.pdf

Ravaghi H, Sajadi H (2014). Research priori-ties for patient safety in Iran. Mirror of Heritage, 16 (4): 358-366.

World Health Organization (2012). Interna-tional Nonproprietary Names (INN) Programme Quality and Safety: Medicines Essential Medicines and Health Products. http://www.who.int/medicines/services/inn/Radical_Book_2012.pdf

Davis CJ (2001). The self-organizing lexical acquisition and recognition (SOLAR) model of visual word recognition. Disser-tation Abstracts International: Section B: The Sciences and Engineering, 62(1-B): 594.

Davis CJ (2010). The spatial coding model of visual word identification. Psychol Rev, 117(3):713-58.

Cheraghi M, Nikbakht Nasr Abadi A, Mo-hammadnejad E et al (2012). Medication errors among nurses in intensive care units (ICU). J Mazandaran Univ Med Sci, 21 (1): 115-119.

Ghasemi M (2011). Factors affecting medi-cation errors in Alzahra Hospital form nurses’ view point. 1st Conference of the Clinical Governance and Quality Im-provement, Iran, Tabriz.

Chanakit T, Napaporn J, Chiempattanaka-john T et al (2013). The survey of looka-like/sound alike (LASA) drugs available in hospitals in Thailand. Afr J Pharm Pharmacol, 7(6):227-39.

Kovacic L, Chambers C (2011). Look-alike, sound-alike drugs in oncology. J Oncol Pharm Pract, 17(2):104-18.

Berman A (2004). Reducing medication er-rors through naming, labeling, and pack-aging. J Med Syst, 28(1):9-29.

Medicines and Healthcare products Regula-tory Agency (MHRA). MHRA guideline for the Naming of Medical Products and Braille Requirements for Name on Label. London: 2009. https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/383713/Naming_of_medicines.pdf

US Food and Drug Administration. Guid-ance for Industry Best Practices in De-veloping Proprietary Names for Drugs. 2014. https://www.fda.gov/downloads/drugs/guidances/ucm398997.pdf

Consultation HC. Review of Drug Names for Look -alike Sound-alike (LASA) At-tributes 2013.

Australian Commission on Safety and Quality in Health Care. National Round Table on Safer Naming, Labelling and Packaging of Medicines. Department of Health and Ageing Therapeutic Goods Administration, 2011. https://www.safetyandquality.gov.au/wp-content/uploads/2012/05/National-Round-Table-on-Safer-Naming-Labelling-and-Packaging-Report.pdf

Emmerton LM, Rizk MF (2012). Look-alike and sound-alike medicines: risks and ‘so-lutions’. Int J Clin Pharm, 34(1):4-8.

Published
2017-11-29
How to Cite
1.
ABOLHASSANI N, AKBARI SARI A, RASHIDIAN A, RASTEGARPANAH M. Assessment of Orthographic Similarity of Drugs Names between Iran and Overseas Using the Solar Model. IJPH. 46(12):1652-8.
Section
Original Article(s)